RxDoctor Payments Data

Patrick Bachoura

Family Practice · Diamond Bar, CANPI 1205330818

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by GSK at 34.6% of the total. Among family practice clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$460in general payments, 2019–2025

Across 22 payments — averaging $20.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$159
  • Pfizer$75
  • Lilly USA, LLC$70
  • AstraZeneca$60
  • Novo Nordisk$30
  • Amgen$20
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$460100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$460 in reported general payments places this provider in the 95th percentile of 2,195 family practice providers in California.

See all family practice providers in California

Medicare billing

Part B allowed, 2024
$84,144
Medicare patients
243
Services billed
800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$38,024
JanuviaSitagliptin Phosphate23$30,822
EliquisApixaban20$24,865
Atorvastatin Calcium299$3,063
Losartan Potassium172$2,004
Levothyroxine Sodium105$1,616
Tamsulosin Hcl72$1,121
Albuterol Sulfate HfaAlbuterol Sulfate49$1,114
Omeprazole69$1,070
Metformin Hcl126$1,024
Amlodipine Besylate145$960
Fluticasone Propionate82$952
Lisinopril101$895
FenofibrateFenofibrate Nanocrystallized13$790
Metoprolol Succinate51$787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$30$38,02431 claims
PfizerEliquis$75$24,86520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,195 family practice providers in California.

Other family practice in Diamond Bar

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →